Deep Apple Therapeutics
Deep Apple Therapeutics discovers novel small-molecule drug candidates for validated targets in inflammatory, metabolic, and endocrine diseases. The company combines ensemble cryo-EM to map receptor conformations with deep learning and large-scale molecular docking of multi‑billion compound libraries generated by its proprietary Orchard.ai algorithm. Its platform is a structure-based, machine-learning driven drug discovery engine built on computational modeling, protein structure determination, and analysis of protein dynamics to prioritize candidates rapidly. Deep Apple operates as a biotech drug discovery company targeting partnerships and preclinical advancement of novel small molecules.
Deep Apple Therapeutics
Deep Apple Therapeutics discovers novel small-molecule drug candidates for validated targets in inflammatory, metabolic, and endocrine diseases. The company combines ensemble cryo-EM to map receptor conformations with deep learning and large-scale molecular docking of multi‑billion compound libraries generated by its proprietary Orchard.ai algorithm. Its platform is a structure-based, machine-learning driven drug discovery engine built on computational modeling, protein structure determination, and analysis of protein dynamics to prioritize candidates rapidly. Deep Apple operates as a biotech drug discovery company targeting partnerships and preclinical advancement of novel small molecules.
